Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
Smruthi Vijayaraghavan, Stacy Moulder, Khandan Keyomarsi, et al.
Targeted Oncology (2017) Vol. 13, Iss. 1, pp. 21-38
Closed Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Mechanistic Insights into the Pharmacological Significance of Silymarin
Karan Wadhwa, Rakesh Pahwa, Manish Kumar, et al.
Molecules (2022) Vol. 27, Iss. 16, pp. 5327-5327
Open Access | Times Cited: 98
Targeting CDK1 in cancer: mechanisms and implications
Qiushi Wang, Ann M. Bode, Tianshun Zhang
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 84
Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
Lin Zhu, Kaiqing Yang, Zhe Ren, et al.
Translational Oncology (2024) Vol. 44, pp. 101945-101945
Open Access | Times Cited: 18
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Renée de Leeuw, Christopher McNair, Matthew J. Schiewer, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 17, pp. 4201-4214
Open Access | Times Cited: 107
Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition
D.J. Wood, S. Korolchuk, Natalie J. Tatum, et al.
Cell chemical biology (2018) Vol. 26, Iss. 1, pp. 121-130.e5
Open Access | Times Cited: 105
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Nicole M. Kettner, Smruthi Vijayaraghavan, Merih Güray Durak, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 13, pp. 3996-4013
Open Access | Times Cited: 104
Therapeutic targeting of transcriptional cyclin-dependent kinases
Matthew D. Galbraith, Heather Bender, Joaquı́n M. Espinosa
Transcription (2018) Vol. 10, Iss. 2, pp. 118-136
Open Access | Times Cited: 92
Plant-Derived Anticancer Agents: Lessons from the Pharmacology of Geniposide and Its Aglycone, Genipin
Solomon Habtemariam, Giovanni Lentini
Biomedicines (2018) Vol. 6, Iss. 2, pp. 39-39
Open Access | Times Cited: 87
DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications
Kah Keng Wong
Cellular Oncology (2020) Vol. 43, Iss. 5, pp. 779-792
Closed Access | Times Cited: 81
Pharmacological properties of indirubin and its derivatives
Yang Lin, Xinyun Li, Wei Huang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113112-113112
Open Access | Times Cited: 56
CDK4: a master regulator of the cell cycle and its role in cancer
Stacey J. Baker, Poulikos I. Poulikakos, Hanna Y. Irie, et al.
Genes & Cancer (2022) Vol. 13, pp. 21-45
Open Access | Times Cited: 48
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, et al.
Cancer Research (2023) Vol. 83, Iss. 19, pp. 3264-3283
Open Access | Times Cited: 23
Slower CDK4 and faster CDK2 activation in the cell cycle
Wengang Zhang, Yonglan Liu, Hyunbum Jang, et al.
Structure (2024) Vol. 32, Iss. 8, pp. 1269-1280.e2
Closed Access | Times Cited: 9
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis
Amina Jamal Laham, Maha Saber-Ayad, Raafat El‐Awady
Cellular and Molecular Life Sciences (2020) Vol. 78, Iss. 2, pp. 603-619
Open Access | Times Cited: 63
Current progress in antimalarial pharmacotherapy and multi-target drug discovery
Natasha Stella Tibon, Chew Hee Ng, Siew Lee Cheong
European Journal of Medicinal Chemistry (2019) Vol. 188, pp. 111983-111983
Closed Access | Times Cited: 61
Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold
Daniel J. Baillache, Asier Unciti‐Broceta
RSC Medicinal Chemistry (2020) Vol. 11, Iss. 10, pp. 1112-1135
Open Access | Times Cited: 53
Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
Bashir Lawal, Yen‐Lin Liu, Ntlotlang Mokgautsi, et al.
Biomedicines (2021) Vol. 9, Iss. 1, pp. 92-92
Open Access | Times Cited: 51
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity
DongHoon Yu, Sabrina Wagner, Martin Schütz, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 158-158
Open Access | Times Cited: 6
The tumour immune microenvironment in oesophageal cancer
Maria Davern, Noel E. Donlon, Robert Power, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 4, pp. 479-494
Open Access | Times Cited: 33
Palbociclib plus endocrine therapy significantly enhances overall survival ofHR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study
Min Jin Ha, Akshara Singareeka Raghavendra, Nicole M. Kettner, et al.
International Journal of Cancer (2022) Vol. 150, Iss. 12, pp. 2025-2037
Open Access | Times Cited: 27
The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
Aadil Javed, Mahdieh Yarmohammadi, Kemal Korkmaz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2848-2848
Open Access | Times Cited: 14
The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment
Bo Ma, Alan Wells, Amanda M. Clark
Seminars in Cancer Biology (2019) Vol. 60, pp. 138-147
Open Access | Times Cited: 38
Multifaceted Roles of Caveolin-1 in Lung Cancer: A New Investigation Focused on Tumor Occurrence, Development and Therapy
Yubo Shi, Jun Li, Xing-Ning Lai, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 291-291
Open Access | Times Cited: 34
Retracted: CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
Yingxiao Cao, Xin Li, Shiqi Kong, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 9, pp. 5135-5145
Open Access | Times Cited: 34
Prostate cancer liver metastasis: Dormancy and resistance to therapy
Bo Ma, Alan Wells, Liang Wei, et al.
Seminars in Cancer Biology (2020) Vol. 71, pp. 2-9
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top